Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0000315066-25-000428
Filing Date
2025-02-07
Accepted
2025-02-07 10:23:35
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 6832
2 exhibit99.txt EX-99 2728
  Complete submission text file 0000315066-25-000428.txt   11284
Mailing Address 245 SUMMER STREET BOSTON MA 02210
Business Address 245 SUMMER STREET BOSTON MA 02210 6175706339
FMR LLC (Filed by) CIK: 0000315066 (see all company filings)

EIN.: 043532603 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A
SIC: 0000

Mailing Address 1050 WALTHAM STREET, SUITE 302 LEXINGTON MA 02421
Business Address 1050 WALTHAM STREET, SUITE 302 LEXINGTON MA 02421 617-314-6297
Keros Therapeutics, Inc. (Subject) CIK: 0001664710 (see all company filings)

EIN.: 811173868 | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-91484 | Film No.: 25599841
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)